These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20207566)

  • 21. Disease management. Getting out from under drug companies' shadows.
    Heimoff S
    Manag Care; 2000 Mar; 9(3):39-40, 42-3. PubMed ID: 11066212
    [No Abstract]   [Full Text] [Related]  

  • 22. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 25. The economics of licensing contracts.
    Mason R; Savva N; Scholtes S
    Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253
    [No Abstract]   [Full Text] [Related]  

  • 26. How to avoid the dangers of disease-specific carve-outs.
    Capitation Manag Rep; 2000 Aug; 7(8):126-7. PubMed ID: 11186760
    [No Abstract]   [Full Text] [Related]  

  • 27. Precipitating factors for pharmaceutical firms.
    McCarthy R
    State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
    [No Abstract]   [Full Text] [Related]  

  • 28. Designing the financial tools to promote universal access to AIDS care.
    Leoni P; Luchini S
    J Health Econ; 2011 Jan; 30(1):181-8. PubMed ID: 21126788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic assessment on medications: effects on pharmaceutical industry and health administration].
    Badía X; Sacristán JA
    Rev Sanid Hig Publica (Madr); 1995; 69(1):17-27. PubMed ID: 7644878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk sharing strategies for disease management programs.
    Norris G
    Dis Manag; 2003; 6(3):139-41. PubMed ID: 14570382
    [No Abstract]   [Full Text] [Related]  

  • 32. [New drugs: money-back guarantee?].
    Steenhoek A; Koopmanschap MA; Franken MG; Rutten FF
    Ned Tijdschr Geneeskd; 2011; 155():A2042. PubMed ID: 21262015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new drug war.
    Parloff R
    Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428
    [No Abstract]   [Full Text] [Related]  

  • 34. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
    Feinberg MB; Gordon L
    Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
    [No Abstract]   [Full Text] [Related]  

  • 35. Health maintenance organizations and the rationing of medical care.
    Luft HS
    Milbank Mem Fund Q Health Soc; 1982; 60(2):268-306. PubMed ID: 6919772
    [No Abstract]   [Full Text] [Related]  

  • 36. HCFA regulates physician risk taking.
    Schwartz HE
    Md Med J; 1996 Aug; 45(8):613-4. PubMed ID: 8772274
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessing an IDS's readiness to operate profitably under a risk contract.
    Garofalo WA
    Healthc Financ Manage; 2001 Feb; 55(2):41-5. PubMed ID: 11271441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redistribution of risk throughout the pharmaceutical industry.
    Scheur BS
    Med Interface; 1994 Oct; 7(10):77-80. PubMed ID: 10137569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.